CA2190394A1 - Virus recombinants, preparation et utilisation en therapie genique - Google Patents

Virus recombinants, preparation et utilisation en therapie genique

Info

Publication number
CA2190394A1
CA2190394A1 CA002190394A CA2190394A CA2190394A1 CA 2190394 A1 CA2190394 A1 CA 2190394A1 CA 002190394 A CA002190394 A CA 002190394A CA 2190394 A CA2190394 A CA 2190394A CA 2190394 A1 CA2190394 A1 CA 2190394A1
Authority
CA
Canada
Prior art keywords
recombinant viruses
preparation
gene therapy
therapy
dyslipoproteinemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002190394A
Other languages
English (en)
Other versions
CA2190394C (fr
Inventor
Patrick Benoit
Patrice Denefle
Michel Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9463811&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2190394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2190394A1 publication Critical patent/CA2190394A1/fr
Application granted granted Critical
Publication of CA2190394C publication Critical patent/CA2190394C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des virus recombinants comportant une séquence d'ADN héterologue codant pour une lipase impliquée dans le métabolisme des lipoprotéines, leur préparation, et leur utilisation thérapeutique, notamment pour le traitement et/ou la prévention des pathologies liées aux dysliproprotéinémies.
CA002190394A 1994-06-02 1995-05-22 Virus recombinants, preparation et utilisation en therapie genique Expired - Lifetime CA2190394C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR94/06759 1994-06-02
FR9406759A FR2720756B1 (fr) 1994-06-02 1994-06-02 Virus recombinants, préparation et utilisation en thérapie génique.
PCT/FR1995/000669 WO1995033840A1 (fr) 1994-06-02 1995-05-22 Virus recombinants, preparation et utilisation en therapie genique

Publications (2)

Publication Number Publication Date
CA2190394A1 true CA2190394A1 (fr) 1995-12-14
CA2190394C CA2190394C (fr) 2008-10-14

Family

ID=9463811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002190394A Expired - Lifetime CA2190394C (fr) 1994-06-02 1995-05-22 Virus recombinants, preparation et utilisation en therapie genique

Country Status (14)

Country Link
US (1) US20130210898A1 (fr)
EP (1) EP0763116B2 (fr)
JP (1) JPH10500859A (fr)
AT (1) ATE248920T1 (fr)
AU (1) AU2620595A (fr)
CA (1) CA2190394C (fr)
DE (1) DE69531678T3 (fr)
FI (1) FI120154B (fr)
FR (1) FR2720756B1 (fr)
IL (1) IL113978A (fr)
MX (1) MX9605988A (fr)
NO (1) NO964894D0 (fr)
WO (1) WO1995033840A1 (fr)
ZA (1) ZA954386B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000426A1 (fr) * 1991-06-25 1993-01-07 Novo Nordisk A/S Lipase pancreatique de mammifere et sa variante
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo

Also Published As

Publication number Publication date
DE69531678D1 (de) 2003-10-09
ZA954386B (en) 1996-03-15
FI964784A (fi) 1996-11-29
EP0763116B2 (fr) 2008-04-23
FR2720756A1 (fr) 1995-12-08
FI964784A0 (fi) 1996-11-29
FR2720756B1 (fr) 1996-07-12
WO1995033840A1 (fr) 1995-12-14
DE69531678T3 (de) 2009-01-29
NO964894L (no) 1996-11-18
IL113978A0 (en) 1995-10-31
ATE248920T1 (de) 2003-09-15
DE69531678T2 (de) 2004-07-08
EP0763116A1 (fr) 1997-03-19
FI120154B (fi) 2009-07-15
CA2190394C (fr) 2008-10-14
NO964894D0 (no) 1996-11-18
AU2620595A (en) 1996-01-04
IL113978A (en) 2006-06-11
JPH10500859A (ja) 1998-01-27
EP0763116B1 (fr) 2003-09-03
US20130210898A1 (en) 2013-08-15
MX9605988A (es) 1997-12-31

Similar Documents

Publication Publication Date Title
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
EP1637608A3 (fr) Vecteur recombinant d'adenovirus et procédés d'utilisation
AU6787894A (en) Adenoviral vectors of animal origin and use in gene therapy
MX9705937A (es) Procedimiento de preparacion de genoma de adenovirus recombinantes.
DE69905170D1 (en) Thiazolopyrimidinderivate
IL181695A0 (en) Methods for cultivating cells and propagating viruses
AU3737297A (en) Bacteriophage-mediated gene therapy
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
IL114904A0 (en) Adenovirus comprising a gene encoding glutathione peroxidase
ZA958128B (en) Viral vectors and use in gene therapy
AU2620595A (en) Recombinant viruses, preparation and use thereof in gene therapy
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
HUP0000853A2 (en) Process for the inactivation of genes which code for enzymes for the catabolism of phenyl acetate, plasmids involved in such process and strains transformed therewith
AU2224197A (en) Drug trial assay system
MX9604026A (es) Virus recombinantes que codifican para una actividad de glutamato-descarboxilasa (gad).
DE69726602D1 (en) Hepatitis b inhibitoren
AU4496196A (en) Recombinant DNA comprising DNA coding for myosin heavy chain SM1 isoform protein inserted into vector DNA, microorganism carrying the recombinant DNA, and an agent for treatment of arteriosclerosis comprising the recombinant DNA
WO1998039417A3 (fr) Lignee cellulaire humaine du foie
GB9508300D0 (en) HIV protease inhibtors for the treatment of aids
WO1998050397A3 (fr) Oligonucleotides chimeriques et leur utilisation
AU6408196A (en) Genetic therapy employing the hhv-6a derived ts gene or polypeptide
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
CA2475337A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
GB9605476D0 (en) HIV gene therapy

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150522